FFO
KNSA icon

Fortitude Family Office’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Fortitude Family Office’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9K Buy
249
+25
+11% +$1.3K ﹤0.01% 605
2026
Q1 		$10.8K Sell
224
-25
-10% -$1.11K ﹤0.01% 630
2025
Q4 		$10.3K Hold
249
– – ﹤0.01% 573
2025
Q3 		$9.67K Hold
249
– – ﹤0.01% 579
2025
Q2 		$6.89K Hold
249
– – ﹤0.01% 678
2025
Q1 		$5.53K Hold
249
– – ﹤0.01% 703
2024
Q4 		$4.92K Hold
249
– – ﹤0.01% 847
2024
Q3 		$6.22K Hold
249
– – ﹤0.01% 716
2024
Q2 		$4.65K Hold
249
– – ﹤0.01% 615
2024
Q1 		$4.91K Hold
249
– – ﹤0.01% 615
2023
Q4 		$4.37K Buy
+249
New +$4.09K ﹤0.01% 727

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Fortitude Family Office's KNSA Position: Q2 2026 in Review

Fortitude Family Office increased its Kiniksa Pharmaceuticals (KNSA) stake by 11% in Q2 2026, buying an estimated $1.3K and bringing the position to 249 shares worth $15.9K. The position accounts for ﹤0.01% of the portfolio, ranked #605.

Fortitude Family Office first reported a position in KNSA in Q4 2023 and has held it in 11 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Fortitude Family Office held 249 shares of Kiniksa Pharmaceuticals worth $15.9K as of Q2 2026.
  • Fortitude Family Office bought 25 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $1.3K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #605 holding.
  • Fortitude Family Office first reported a position in Kiniksa Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.